Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study.
<h4>Introduction</h4>Combined inhaled long-acting beta-agonists and corticosteroids (LABA+ICS) are costly. They are recommended in severe or very severe chronic obstructive pulmonary disease (COPD). They should not be prescribed in mild or moderate disease. In COPD ICS are associated wit...
Guardado en:
Autores principales: | Patrick White, Hannah Thornton, Hilary Pinnock, Sofia Georgopoulou, Helen P Booth |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bb1c1e1fedbf4b8a8d11f72dd1dc9928 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
por: Anthony D’Urzo, et al.
Publicado: (2017) -
Dynamics of inhaled corticosteroid use are associated with asthma attacks
por: Joy Lee, et al.
Publicado: (2021) -
Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice
por: James D. Chalmers, et al.
Publicado: (2017) -
Blue inhalers: blowing hot and cold
por: Salina Ahmed, et al.
Publicado: (2017) -
Pharmaco-Metabolomics of Inhaled Corticosteroid Response in Individuals with Asthma
por: Priyadarshini Kachroo, et al.
Publicado: (2021)